Janát-Amsbury Margit Maria, Yockman James William, Anderson Matthew Linley, Kieback Dirk Günter, Kim Sung Wan
Baylor College of Medicine, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Faculty Center, Dryden Road, Suite 1143, Houston, Texas 77030, USA.
Anticancer Res. 2006 Sep-Oct;26(5A):3223-8.
The in vivo feasibility of the previously established ID8 and ID8-VEGF ovarian cancer models for non-viral IL-12 gene delivery by itself or in combination with paclitaxel chemotherapy, was investigated in C57BL/6 black mice. The syngeneic mouse ovarian epithelium (MOSE) cancer cell line and its more aggressive variant, a VEGF-modified strain, were used to perform these experiments. Tumor growth and survival were observed in C57/BL6 mice, inoculated with both ID8 substrains. The superiority of IL-12 gene therapy in comparison to conventional paclitaxel chemotherapy in terms of tumor size and survival was demonstrated.
在C57BL/6黑色小鼠中，研究了先前建立的ID8和ID8-VEGF卵巢癌模型用于单独或联合紫杉醇化疗进行非病毒IL-12基因递送的体内可行性。使用同基因小鼠卵巢上皮（MOSE）癌细胞系及其更具侵袭性的变体（一种VEGF修饰菌株）进行这些实验。在接种了两种ID8亚株的C57/BL6小鼠中观察肿瘤生长和存活情况。结果表明，在肿瘤大小和存活方面，IL-12基因疗法相较于传统紫杉醇化疗具有优越性。
